Tag:

Roche

Latest Headlines

Latest Headlines

Italian fraud squad raids drug agency in Roche-Novartis probe

Italian finance police searched the offices of the Italian Medicines Agency, looking for evidence in a criminal probe of potential fraud and market manipulation by the Swiss drugmakers Novartis and Roche. Officials have been investigating allegations that the two companies colluded to boost sales of Lucentis, their eye drug, by sidelining off-label use of the drug's close cousin, Avastin.

Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test

Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.

Study: Subbing Avastin for Lucentis could save U.S. $3B on eye treatment

Doctors have long repurposed Roche's Avastin for the eye in place of using the company's pricier Lucentis to save money. Now, a study says the U.S. could save almost $3 billion a year if Medicare patients received the cheaper drug--a prospect Roche isn't so keen on.

Roche makes $350M move for DNA sequencing business

After failing to buy Illumina in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business.

Roche partners with Roche on 'breakthrough' PD-L1 cancer program

Today, Roche put out the word that their PD-L1 drug MPDL3280A won the FDA's coveted breakthrough therapy designation, potentially putting it on an inside track at the agency, which has been hurrying along new medicines in the pipeline.

Roche, Novartis face $1.6B in damages on Italy's Lucentis collusion ruling

Three months ago, antitrust authorities in Italy fined Novartis and Roche $251 million on charges they colluded to protect sales of their eye drug, Lucentis. Now, that country's Health Ministry is seeking further damages.

Roche, undaunted by reimbursement cutbacks, sees no need for Dx price reductions

Execs with Roche's diagnostics arm remain bullish about U.S. growth prospects even as reimbursement cuts place new pressures on the sector overall. An executive with the company anticipates booming demand to the point that price reductions aren't on the table.

Roche gets thumbs up for CLL use of Gazyvaro in EU

Gazyva, Roche's successor to Rituxan, is already approved in the U.S. for first-line use on chronic lymphocytic leukemia (CLL) and appears poised for the same in Europe. The EU Committee for Medicinal Products for Human Use (CHMP) today recommended it for approval there.

Roche becomes latest target of China corruption crackdown

The country is in the midst of a full-blown corruption investigation aimed largely at Big Pharma, and now it has picked another target: Swiss drugmaker Roche.

Roche investments for boosting manufacturing now exceed $1B

Roche laid out an extensive plan last year to expand and upgrade its biologics manufacturing network, spanning 5 years and three countries, including at its headquarters in Basel, Switzerland. Now the drugmaker says it plans to add to its small-molecule drugmaking capabilities in Basel.